Navigation Links
PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
Date:2/11/2010

MONTEREY, Calif., Feb. 11 /PRNewswire/ -- PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System.  The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

"We are very pleased to move forward with this investigational treatment aimed at preventing bronchiolitis obliterans, which is an incurable small airway disease in lung transplant recipients.  This study has been designed with advice from the European Medicines Agency under L-CsA's orphan drug designation status," said Manfred Keller, chief scientific officer and executive vice president of PARI Pharma.

PARI Pharma's Phase 2b trial is a multi-center, randomized, double-blind, placebo controlled, parallel group, dose-finding study to investigate the safety and efficacy of L-CsA in doses of 10mg/day and 20mg/day to prevent bronchiolitis obliterans in recipients of lung transplants.

"We are seeing early success from our L-CsA program. This underscores PARI Pharma's unique position to combine formulation expertise with our advanced aerosol delivery technology to develop best in class therapies for unmet medical needs," added Martin Knoch, president of PARI Pharma.

Positive data regarding human lung deposition and distribution of L-CsA was published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery last year, and clinical as well as preclinical data will be presented in April at the Annual Meeting of the International Society of Heart and Lung Transplantation in Chica
'/>"/>

SOURCE PARI Pharma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Every day, their baby stopped breathing, his collapsed ... April and Bryan Gionfriddo watched helplessly, ... "Quite a few doctors said he had a good ... April Gionfriddo , about her now 20-month-old son, Kaiba. ... we would take it and run with it." ...
(Date:5/23/2013)... TARRYTOWN, N.Y. , May 23, 2013 /PRNewswire/ ... reconstruction following mastectomy is an appropriate option ... mutations seeking to surgically reduce their breast cancer ... involves a gradual expansion process and a second ... of implants in the same surgery as mastectomy ...
(Date:5/23/2013)... Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s 1 ... on October 14 th -15 th in ... most innovative city in the world by the ... Nation." BrainTech Israel 2013 will showcase the latest ...
Breaking Medicine Technology:Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... Mich., Feb. 16, 2012  Waltonen Engineering, Inc., a ... announce that it has been awarded a U.S. ... Services (PES) Contract. "Waltonen currently ... Tank Automotive Research Development Engineering Center (TARDEC), Tank ...
... likelihood that Medicare beneficiaries are not receiving necessary medical ... urging Congress to adopt the Market Pricing Program ... home medical equipment and services, or durable medical equipment ... and Medicaid Services (CMS), which implemented the bidding program ...
Cached Medicine Technology:American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 2American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 3American Association for Homecare Calls for Market-Based Alternative to Medicare's Bidding Program; Cites Lack of Access for Beneficiaries 4
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... dedicated to protecting the rights of victims injured by ... that Senior Litigation Counsel Matthew J. McCauley has been ... entitled In Re: Mirena IUD Products Liability Litigation (Case ... states that Co-Lead and Liaison Counsel are to submit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Teen birth rates in the ... to a new government report. Overall, the rate of ... one half from 1991 to 2011 -- from about 62 ... 1,000. From 2007 to 2011, the most recent time ... 31. During that time, rates fell at least 30 ...
(Date:5/23/2013)... (HealthDay News) -- A shortage of a critical tuberculosis ... the United States to contain the spread of the ... drug, isoniazid (INH), was first used in 1951 and ... core of any first-line treatment for tuberculosis (TB). Patients ... according to the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... good job of aggressively treating the early stages of ... diagnosis. The study involved 467 hospitals spread across 12 ... that patients may be treated less aggressively when they ... able to confirm the diagnosis,” said Chadwick Miller, M.D., ...
... Heart failure patients with untreated sleep apnea are more likely to ... ,The study followed 164 patients with heart failure for ... apnea (OSA) had double the death rate of those patients who ... OSA, the death rate was 24% in contrast to 12% for ...
... in the fight against obesity has started delivering results in ... pilot program was started in one of the middle schools ... eating habits among school children. ,Today nearly ... this three year old program called ‘Healthy School.’ ...
... that smoking and binge drinking among teenage girls have ... the health risks seem less important than those of ... young people correctly see cigarettes and alcohol as a ... to reflect that, Ofsted opined. Pupils also felt let ...
... NHS services’, UK ‘s Health Minister Patricia Hewitt launched ... select their hospital and doctor, as well as access information on ... to put patients at the heart of the NHS and making ... a crucial part of that. “Patients will soon be able to ...
... welcomed the Government’s decision to officially recognise the Australian ... for rural GPs. ,“Rural GPs are the ... ,“Formal recognition for rural GPs who complete ... workforce in rural and regional areas.” ,The ...
Cached Medicine News:Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 2Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 3Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 3Health News:Campaign Against Obesity Taken to Schools in US 2Health News:Parents To Blame For Soaring Counts Of Binge-Drinkers And Smokers 2Health News:NHS Online- Promise Of ‘Choices’ To Patien 2